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Summary 
We have previously shown using gene targeting that 
PU.1 is essential for the development of lymphold and 
myeloid lineages during fetal liver hematopoiesis. We 
now show that PU.1 is required for the maturation of 
yolk sac-derived myeloid progenitors and for the dif- 
ferentiation of ES cells into macrophages. The role of 
PU.1 in regulating target genes, thought to be critical 
in the development of monocytes and granulocytes, 
has been analyzed. Early genes such as GM-CSFR, 
G-CSFR, and myeloperoxidase are expressed in 
PU.l-‘- embryos and differentiated PU.l-‘- ES cells. 
However, the expression of genes associated with 
terminal myeloid differentiation (CD1 1 b, CD64, and 
M-CSFR) is eliminated in differentiated PU.l-‘- ES 
cells. Development of macrophages is restored with 
the introduction of a PU.1 cDNA regulated by its own 
promoter. The PU.l-‘- ES cells represent an important 
model for analyzing myeloid cell development. 
Introduction 
Hematopoiesis is a multistage developmental process in 
which a pluripotent hematopoietic stem cell (HSC) gives 
rise to monocytes, granulocytes, lymphocytes, megakary- 
ocytes, and erythrocytes. As multipotential progenitor 
ceils undergo monocytic development, they differentiate 
into proliferating monoblasts, promonocytes, monocytes, 
and finally macrophages. Granulocytic development in- 
volves the differentiation of progenitors into myeloblasts, 
promyelocytes, myelocytes, and then neutrophils. Spe- 
cific markers can be used to distinguish monocytic and 
granulocytic cells at particular stages of maturation. For 
example, the CD34 surface antigen is expressed on stem 
cells and myeloid progenitor cells but expression de- 
creases as these cells differentiate (Berenson et al., 1966, 
1991). Myeloperoxidase (MPO) is an enzyme found exclu- 
sively in monocytes and granulocytes (Tobler et al., 1966; 
Lubbert et al., 1991). MPO mRNA can be detected in late 
myeloblastic, promyelocytic, and promonocytic stages of 
differentiation but decreases as cells mature (Tobler et 
al., 1966; Rosmarin et al., 1989). The CD1 1 b leukocyte 
integrin subunit is initially expressed at the monoblastic 
and myelocytic stages of development but expression in- 
creases during monocytic and granulocytic differentiation 
(Griffin et al., 1981; Rosmarin et al., 1989). Receptors for 
colony-stimulating factors (CSFR) can also be used as 
myeloid differentiation markers. The granulocyte/macro- 
phage (GM)-CSFR is expressed on multipotent progeni- 
tors as well as committed myeloid cells (Park et al., 1986; 
Wognum et al., 1994). G-CSFR is also expressed on 
multipotent progenitors, but as these cells differentiate, 
its expression is restricted to granulocytic precursors and 
terminally differentiated neutrophils (Nagata, 1990; Demi- 
tri and Griffin, 1991; Tsuji et al., 1992). 
Insight into myeloid (monocytic and granulocytic) devel- 
opment has primarily been obtained from studies of adult 
bone marrow cells. However, this system does not neces- 
sarily reflect myeloid development during early ontogeny, 
when the yolk sac and fetal liver are the primary sites of 
hematopoiesis. Hematopoiesis in the developing mouse 
is initiated in the yolk sac on day 7 of gestation. The hema- 
topoieticcells present in the yolksac include multipotential 
progenitors, erythroid cells, and primitive macrophages 
(Cline and Moore, 1972). Previous studies have demon- 
strated that the earliest yolk sac macrophages differ in 
enzyme cytochemistry, structural characteristics, and 
functional properties when compared with macrophages 
generated at later stages of development (Takahashi et 
al., 1989). Furthermore, early macrophage development 
in the yolk sac may differ from fetal liver and adult macro- 
phage development (Naito, 1993). Beyond day 12 of gesta- 
tion, yolk sac hematopoiesis declines and the fetal liver 
becomes the predominant hematopoieticorgan until birth. 
During fetal liver hematopoiesis, myeloid cells increase in 
numbers and include both monocytes and neutrophils. 
Although the factors that control myeloid development in 
early ontogeny are largely unknown, it is probable that 
they include lineage-restricted transcription factors. 
The transcription factor PU.l has previously been impli- 
cated as an important regulator of hematopoiesis. PU.l 
is highly expressed in B lymphocytic, granulocytic, and 
monocytic cells and to a lesser extent in immature ery- 
throid cells (Klemsz et al., 1990; Galson et al., 1993; Hro- 
mas et al., 1993; Chen et al., 1995). PU.l has many pre- 
sumptive targets in the B and myeloid lineages. In the 
monocytic and granulocytic lineages, many of the candi- 
date PU.l target genes play important roles in develop 
ment, survival, and function. These include the genes for 
CD1 1 b, CD18, CD64(FcyRI), MPO, GM-CSFR, G-CSFR, 
and M-CSFR (Venturelli et al., 1989; Pahl et al., 1993; 
Perez et al., 1993; Smith et al., 1994; Zhang et al., 1994; 
Hohaus et al., 1995; Rosmarin et al., 1995). We have re- 
cently analyzed hematopoietic defects caused by a tar- 
geted mutation in the murine PU.l locus (Scott et al., 
Immunity 
704 
1994). Disruption of the PU.l gene results in prenatal le- 
thalityas PU.l-‘-embryosdie between days 16-18of ges- 
tation. Mutant embryos produce normal numbers of mega- 
karyocytes and erythroid progenitors; however, 
enucleated erythrocytes are reduced in some day 18.5 
embryos. An invariant consequence of the mutation is a 
multilineage defect in the development of B and T lympho- 
cytes, monocytes, and granulocytes. The development of 
B and T lymphocytes is completely eliminated by the PU.l 
mutation. Histological staining for lysozyme and myeloper- 
oxidase as well as FACs analysis (CD1 1 b, Gr-1) demon- 
strated an inhibition of myeloid development in the fetal 
liver. 
In this report, we address the following issues concern- 
ing PU.l and the regulation of myelopoiesis (monocytic 
and granulocytic development): Is PU.l required for yolk 
sac myelopoiesis? Which myeloid target genes are regu- 
lated by PU.l? Where does the block in myelopoiesis oc- 
cur in the absence of PU.l? In these studies, we demon- 
strate that myelopoiesis is defective in PU.l-I- yolk sacs 
in addition to PU.V fetal livers. Thus, PU.l is different 
from other hematopoietic transcription factors (erythroid 
Kruppel-like factor; EKLF), c-myb, and GATA-3 (Mucenski 
et al., 1991; Nuezet al., 1995; Perkins et al., 1995; Pandolfi 
et al., 1995) which are only essential for fetal liver hemato- 
poiesis. We have analyzed the ability of PU.l -I- embryonic 
stem (ES) cells to differentiate into myeloid cells in vitro. 
PU.l-‘- ES cells failed to differentiate into macrophages 
and neutrophils. We found that several early myeloid 
genes thought to be PU.l targets are transcribed normally 
in PU.l-‘- differentiated ES cells. However, later myeloid 
genes are expressed at lower levels or are not transcribed 
at all. Therefore, the earliest events in myelopoiesis occur 
in the absence of PU.l but terminal myeloid differentiation 
is blocked. Finally, we have rescued the myeloid defect 
in mutant ES cells by introducing a PU.l cDNA linked to 
its own promoter. Introduction of this construct into PU.l -I- 
ES cells restores the expression of PU.1 and the produc- 
tion of macrophages in vitro. 
Results 
PU.l Is Required for the In Vitro Differentiation 
of Yolk Sac Myeloid Progenitors 
In the developing mouse embryo, hematopoiesis is initi- 
ated in the yolk sac blood islands on day 7.5 of gestation. 
By day 9, macrophages can be detected in addition to 
erythroid cells(Cline and Moore, 1972). To assess whether 
the PU.1 mutation has an effect on embryonic erythropoie- 
s/s, yolk sacs were analyzed by flow cytometry to deter- 
mine whether the PU.l -I- embryos contained normal num- 
bers of erythroid cells. When day 10.5 yolk sac erythroid 
cells were analyzed by staining with TERl19-fluorescein 
isothiocyanate (FITC), TER-119’ cells represented ap- 
proximately 750/o-80% of the total number of cells in all 
PU.l+‘+, PU.l+‘-, and PU.l-‘- samples (data not shown). 
These results demonstrate that PU.l is not required for the 
generation of yolk sac erythroid precursors as previously 
shown for the fetal liver (Scott et al., 1994). Yolk sac stem 
cells arecapable of developing into multiple hematopoietic 
lineages. To determine the effect of the PU.l mutation 
on primitive progenitors, hematopoietic colony formation 
assays were performed at day 8.5 and 10.5 of gestation. 
Yolk sacs were disaggregated and cultured in methylcellu- 
losemedium, whichsupportsthegrowthoferythroid, meg- 
akaryoid and myeloid cells. Colony morphology was con- 
firmed by cytocentrifugation and May-Grunwald-Giemsa 
staining. The results of the colony forming assays are sum- 
marized in Table 1. PU.l+‘+ and PU.l+‘- yolk sac platings 
were scored for granulocyte-erythrocyte-megakaryo- 
cyte-macrophage (GEMM), granulocyte-macrophage 
(GM), granulocyte (G), and macrophage (M) colonies. Ex- 
amples of these cells are shown in Figure 1. The PU.l+‘+ 
and PU.l+‘- day 10.5 yolk sacs produced approximately 
12% GEMM, 10% GM, 26% M, and 3% G (Table 1). In 
contrast, no GEMM, GM, M, or G colonies were detected 
in platings of day 8.5 or day 10.5 PU.l-‘- yolk sacs (Table 
1). At day 8.5, yolk sac progenitors produce erythroid (E) 
colonies containing primitive red cells (nucleated), which 
have been shown to differ from definitive (enucleated) red 
cells in hemoglobin expression and growth factor require- 
ments (Keller et al., 1993). Primitive erythroid cells could 
be detected in cytospin preparations of day 8.5 E colonies, 
whereas definitive red cells were produced in day 10.5 E 
colonies (Figure 1). In addition to E colonies, there were 
many colonies that contained both E and megakaryocytic 
cells (E-Meg). As shown in Table 1, primitive erythroid, 
definitive erythroid, and megakaryoid development occurs 
in the absence of PU.l. Although the number of erythroid 
and megakaryoid colonies was lower in day 10.5 PU.l-I- 
yolk sacs, this decrease was not statistically significant. 
The effect of the PU.l mutation on fetal liver hematopoietic 
progenitors has also been characterized using in vitro col- 
ony-forming assays (Scott et al., 1994; unpublished data). 
The PU.l+‘+, PU.l+‘-, and PU.l-‘- fetal liver progenitors 
generated comparable numbers of E and Meg colonies. 
Both the PU.l+‘+ and PU.l+‘- fetal liver cells gave rise to 
GEMM (200/o), GM (15%) G (20%), or M (20%) colonies, 
whereas none of these colonies were produced by the 
PU.l-‘- fetal liver cells. Thus, PU.l is required for the de- 
velopment of monocytic and granulocytic lineages at the 
earliest detectable stages of hematopoiesis in the yolk sac 
and fetal liver. 
The Effect of PU.l on Yolk Sac Yyeloid 
Gene Expression 
To determine whether candidate myeloid target genes for 
PU.l were being expressed, RT-PCR analyses were per- 
formed on RNA obtained from pooled samples of day 10.5 
yolk sacs, using primers specific for GM-CSFR, G-CSFR, 
MPO, CD11 b, CD18, and M-CSFR. RNA isolated from 
the mature macrophage cell line J774.1 was used as a 
positive control. To compensate for variable RNA and 
cDNA yields, the quantity of cDNA synthesized was cali- 
brated using the relative expression level of hypoxanthine 
phosphoribosyltransferase (HPRT) as a standard. A series 
of cDNA dilutions and variations in cycle number were 
tested to determine whether the RT-PCR reactions were 
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Figure 1. Representative Cells from Yolk Sac Colony-Forming Assays 
May-Grunwald-Giemsa-stained hematopoietic cells in colonies obtained from PU.l+‘+ (a, b, and c) and PU.V- yolk sac progenitors (d, e, and 9. 
Megakaryocytes and erythroid cells (arrows) from an E-Meg colony are apparent in (a), while macrophages from an M colony are present in (b). 
(c) shows both macrophages and neutrophils (arrows) from a GM colony. A nucleated primitive erythrocyte from a day 8.5 yolk sac E colony is 
shown in (d). Proerythroblasts and enucleated definitive erythrocytes (arrows) from a day 10.5 yolk sac E colony are shown in (e); megakaryocytes 
from an E-Meg colony are shown in (9. The number of colonies produced from the yolk sac platings are shown in Table 1. 
semiquantitative(data notshown). From multiple FIT-PCR 
analyses, it wasevident that the expression of CD1 1 b was 
lower in the PU.l-‘- yolk sac cells (Figure 2). However, 
the expression of other myeloid genes, including GM- 
CSFR, G-CSFR, MPO, CD18, and M-CSFR were not af- 
fected bythe PU.l mutation. RT-PCR analysisof day 15.5 
fetal liver RNA showed that GM-CSFR, G-CSFR, MPO, 
CD18, and M-CSFR were also expressed in PU.l-‘- em- 
bryos (data not shown). The expression of GATA-2, which 
occurs in progenitors of erythroid, myeloid, and lymphoid 
lineages, was also unaffected by the mutation. In both the 
fetal liver and yolk sac preparations, the failure to see 
pronounced effects on M-CSFR or G-CSFR expression 
may be attributed to the presence of nonmyeloid cells that 
are capable of expressing these genes. M-CSFR is ex- 
pressed in trophoblastic cells and in unidentified cells in 
the visceral yolk sac (Regenstreif and Rossant, 1989). 
G-CSFR is predominantly found in precursor and mature 
neutrophils, but is also expressed in placenta and tropho- 
blastic cells (Uzumaki et al., 1989). However, GM-CSFR, 
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Table I. Summary of Hematopoietic Colony Formation 
Stage of Development Genotype 
Number of samples 
analyzed 
Average Number of Colonies per Yolk Sac 
E E-Meg Meg GEMM GM M G 
+I+ 5 17 2 1 2 0 4 0 
Day 8.5 yolk sacs +I- 10 17 2 1 4 1 4 0 
-/- 5 13 3 1 0 0 0 0 
+I+ 11 11 26 12 12 7 25 3 
Day 10.5 yolk sacs +I- 18 10 19 9 10 9 22 2 
-- l 10 5 18 6 0 0 0 0 
Yolk sacs were dissected on day 8.5 and 10.5 of gestation and disrupted in a 0.25% collogenase solution. Yolk sac cells (approximately I@) were 
plated in 1.5 ml of a-methylcellulose supplemented with Lglutamine, t&mercaptoethanol, penicillin/streptomycin, murine spleen cell-conditioned 
medium, and erythropoietin. After 7 days of incubation, hematopoietic colonies were scored as E (erythroid), E-Meg (erythroid-megakaryocyte), 
Meg (megakaryocyte), GEMM (granulocyte, erythroid, megakaryocyte, macrophage), GM (granulocyte-macrophage), M (macrophage), and G 
(granulocyte). 
MPO, and CD1 8 have not been detected in nonhematopoi- 
etic tissues (Park et al., 1988; DiPersio et al., 1988; Tobler 
et al., 1988; Wognum et al., 1994; Lubbert et al., 1991). 
These results suggest that some myeloid target genes for 
PU.l are still expressed normally in its absence. 
Generation of PU.l Homozygous Mutant ES Cells 
Given the complexity of the fetal tissues, we wanted to 
analyze myeloid development in a simplified system: the 
c G-CSFR 573 bp 
m+ MPO 695 bp 
Figure 2. Gene Expression in Day 10.5 Yolk Sacs 
Yolk sacs were dissected and pooled according to genotype. RNA 
was prepared by homogenizing PU.1 wild-type (“), heterozygous (“-), 
and homozygous mutant (-‘-) yolk sacs (four each) in Trirol RNA re- 
agent. RT products were normalized by HPRT expression. The RT- 
PCR procedure was carried out as described in the text. 
in vitro differentiation of mouse ES cells. This in vitro differ- 
entiation system is capable of producing multiple hemato- 
poietic lineages including macrophages, neutrophils, and 
erythrocytes (Keller et al., 1993). We generated PU.l-I- 
ES cells by sequential gene targeting (Figure 3). PU.l+‘- 
ES cells contain one intact allele and one allele that is 
disrupted by the positive selectable marker PGK-neo 
(Scott et al., 1994). The neo gene replaces a portion of 
exon 5 that encodes the DNA binding domain of PU.l. 
The targeting vector pES-PU.l was designed similarly to 
delete a portion of exon 5 of the intact allele and replace 
it with a second selectable marker, PGK-hyg. Targeted 
CCE ES cells were screened by Southern blot analysis 
of EcoRI-digested DNAs. Figure 3C shows examples of 
PU.l+‘+ ES cells, PU.l+‘- cells, and three independent 
PU.l-‘- clones. Prolonged autoradiography (2-3 weeks) 
demonstrated that these ES cells did not contain any resid- 
ual PU.l wild-type allele due to contaminating heterozy- 
gous cells. 
PU.l Is Required for the Development of Myeloid 
Cells In Vitro 
During in vitro differentiation, ES cells form three- 
dimensional structures, known as embryoid bodies (EBs), 
which contain a variety of embryonic cells (Doetschman 
et al., 1985; Keller et al., 1993). When differentiated in 
0.9% methylcellulose medium, EBs produce primitive 
erythrocytes, definitive erythrocytes, macrophages, rare 
neutrophils, and early megakaryocytes (Keller et al., 
1993). To determine whether neutrophils and monocytes/ 
macrophages were being produced, cytospin prepara- 
tions were performed on PU.l+‘+, PU.l+‘-, and PU.l-‘- EBs 
after 11 days of in vitro differentiation. When stained with 
May-Grunwald-Giemsa, no monocytes or macrophages 
were detected in the PU-‘- EBs (see Figure 8). These 
cells were readily detected in the PU.l +I+ and PU.l +I- EBs. 
To assess further whether macrophages were being pro- 
duced in the PU.l-‘- EBs, dissociated EBs were allowed 
to adhere to 8-well chamber slides and were then stained 
with the macrophage-specific markers, F4/80 and CD1 1 b. 
As shown in Figure 4, adherent macrophages form charac- 
teristic pseudopodia. The cells from the wild-type and het- 
erozygous EBs showed macrophages that stained in- 
B 
Figure 3. PlJ.1 Targeting Scheme 
PU.1 
Heterozygote 
(A) The targeting vector (pES-PUT) was de- 
signed to delete the DNA binding domain of 
exon 5 and replace it with the positive se- 
lectable marker PGK-net (Scott et al., 1994). 
To enrich for homologous recombination 
events, the negative selectable marker PGK- 
fkwasemployed. Clonesthat are heterozygous 
for the mutation were selected in G41B/gan- 
cyclovir and have the genotype shown. 
(6) The pES-PU.1 construct was transfected 
into the heterozygous mutant cells and se 
lected with hygromycin B (0.125 mg/ml) to ob- 
tain homozygous mutant cells having the con- 
figuration shown. 
(C) Genotypic analysis of targeted ES cell 
clones. DNA was digested with EcoRl and hy- 
bridized with the 5’ probe, which detects an 3 
pEs-PU.l 
kb wild-type PU.l allele and a 5 kb mutated 
PU.l allele. Symbols are as follows: +I+, wild 
type; +‘-, heterozygote; -I-, homozygous mutant. 
PU.l Null 
C 
“0MOZYCO”S MUTANT (-I-) 
Figure 4. Identification of Macrophages by lmmunocytochemical Staining 
PUl’“, Pu.l+‘-, and PU.l+- ES cells were differentiated for 11 days in methylcellulose cultures. The EBs were then dissociated and allowed to 
adhere to multiwell chamber slides for 12 hr. The adherent cells were fixed and stained using the macrophage-specific antibody F4/50 and the 
Vectastain ABC-alkaline phosphatase kit (Vector Laboratories). The upper panels show phase contrast photomicrographs, while the lower panels 
present bright field photomicrographs. 
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tensely with the F4/80 antibody (Figure 4). Although 
adherent cells were recovered from the PU.l -I- EBs, none 
of these cells stained with either F4/80 or CD1 1 b (Figure 
4; see Figure 8). Therefore, based on May-Grunwald- 
Giemsa, F4/80, and CD1 1 b staining, no macrophages 
were produced by PU.l+ ES cells. 
Myeloid Gene Expression during Wild-Type 
ES Cell Differentiation 
The time course of myeloid gene expression during ES 
cell differentiation is shown in Figure 5, where wild-type 
ES cells were differentiated and RNA harvested at days 
2-11 and 13. The amount of RNA was normalized ac- 
cording to the expression of 8-actin and HPRT. PU.l ex- 
pression was first detected at day 5 of differentiation, and 
increased gradually until day 11. By day 13, its expression 
decreased. The expression of PU.l defines a time frame 
in which PU.l-regulated genes are most likely to be ex- 
pressed. The expression of a number of myeloid-specific 
genes was analyzed, including CD1 1 b, CD14(the receptor 
for bacterial lipopolysaccharide), CD18, and M-CSFR. 
The two subunits that form the Mac-l adhesion molecule, 
CD1 1 b and CD1 8, were first detected on day 8 in EBs and 
were present at lower levels by day 13. CD1 4 mRNA was 
present as early as day 5 and levels increased steadily to 
day 11. The high affinity receptor for immunoglobulin G 
(IgG) (Allen and Seed, 1989), CD64 (FqRI), was ex- 
pressed from days 8-13. B7.2 is expressed on antigen- 
presenting cells, and serves as the costimulatory signal 
necessary for T cell activation (Freeman et al., 1993). It 
was expressed in a pattern similar to CD1 1 b and CD64: 
days 8-l 3. M-CSFR gene expression during EB develop- 
ment starts on day 8, peaks at day 11, and decreases by 
day 13. The proto-oncogene c-fes is a tyrosine kinase that 
is expressed in monocytes, macrophages, neutrophils, 
and their precursors. It has also been detected in purified 
CD34+ hematopoietic stem cells and a variety of embry- 
onic cells (Care et al., 1994). c-fes showed a different pat- 
tern of expression than the rest of the myeloid genes in 
that it is expressed at low levels in undifferentiated cells. 
However, its expression increased significantly with differ- 
entiation. 
PU.l Is Required for Late Stage Myeloid 
Gene Expression 
The time course analysis of differentiating ES cells showed 
that day 11 was optimal for expression of myeloid-specific 
genes. Accordingly, myeloid gene expression was ana- 
lyzed by RT-PCR using RNA derived from day 11 cultures 
of PU.l+‘+, PU.l+‘-, and PU.1 ES cells. As expected, 
PU.l mRNA was not detected in mutant EBs (Figure 6A). 
The early myeloid genes analyzed included CD34, GM- 
CSFR, G-CSFR, MPO, and c-fes. CD34 is expressed on 
murine stem cells (CFU-S) (Krause et al., 1994). From our 
in vitro differentiations it was clear that CD34 was ex- 
pressed in undifferentiated ES cells, and in differentiated 
PU.l+‘+, PU.l+‘-, and PU.l+ EBs. CD34 was not ex- 
pressed in the mature mouse macrophage line J774.1, as 
expected from human expression data. GM-CSFR was 
expressed in both the differentiated and undifferentiated 
Figure 5. Time Course of Gene Expression during In Vitro Differentia- 
tion of Wild-Type CCE ES Cells 
El3s were harvested on various days and RNA was extracted. Molecu- 
lar weight markers are shown in the first lane of each gel. b-actin levels 
were normalized sc that there would be equal amounts of RNA in each 
lane. The expression of PU.1 and myeloid-specific genes are shown. 
PU.l+‘+ ES cells as well as in the PU.l+‘- and PU.l-‘- EBs. 
MPO was not expressed in undifferentiated ES cells or in 
the terminally differentiated macrophage cell line, J774.1. 
However, it was expressed in the differentiated PU.l+‘+, 
PU.l+“, and PU.l+EBs. Unlikeotherearly myeloidgenes 
(GM-CSFR, G-CSFR, MPO), c-fes expression was af- 
fected by the PU.l mutation. c-fes expression was detect- 
able in PU.l+‘+ and PU.l+‘- EBs but was reduced in the 
PU.l-‘- EBs. This gene was the only early myeloid gene 
of those analyzed whose expression was significantly di- 
minished in the PU.l-‘- EBs. 
When RT-PCR analysis was carried out on genes ex- 
pressed later in myeloid development, the expression of 
several genes wassignificantly reduced by the PU.1 muta- 
tion. In the PU.l-‘- EBs, CD18 was notably lower, whereas 
CD1 1 b, M-CSFR, and CD64 were completely absent (Fig- 
ure 6B). All of these genes were not expressed in the undif- 
ferentiated ES cells, but were expressed in the PU.l+‘+ 
and PU.l+‘- EBs, as well as in J774.1. P-major globin, 
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Figure 6. Expression of PU.l Target Genes in ES Cells 
(A) Expression of early myeloid markers. ES cells were differentiated to day 11 and harvested for RNA. RT-PCA was performed with primers 
specific for PU.1, CD&l, GATA-2, GM-CSFR, G-CSFR, MPO, c-fes, and HPRT as a control. Three independently derived PU.1 homozygous 
mutant ES cell lines ((-) were tested for myeloid gene expression. J774.1 is a mature macrophage cell line. Symbols are as follows: M, molecular 
weight marker; +‘+, wild type; +‘-, heterozygote; -I-, homozygous mutant. 
(B) Expression of late myeloid markers. Samples were prepared as described in Figure 2, and RT-PCR was performed for the myeloid genes 
CD1 1 b, CD1 6. CD64, and M-CSFR. D-olobin expression was assaved to determine the extent of erythropoiesis, and p-actin was used to demonstrate - 
equality of RNA amounts. 
which is expressed exclusively in the erythroid lineage, 
was not altered by the PU.l mutation indicating that ery- 
throid production proceeds normally in the PU.l-‘- EBs. 
Taken together, the cytological and RT-PCR data demon- 
strated that PU.l is not essential for early myeloid gene 
expression, but becomes critical at later stages. 
Rescue of the Myeloid Deficiency in PU.l-‘- ES 
Cells by the Introduction of a PU.l cDNA 
PU.l -I- ES cells fail to produce mature macrophages upon 
in vitro differentiation into EBs. To correct this deficiency, 
we constructed a plasmid containing the PU.l cDNA regu- 
lated by a 6.0 kb PU.l 5’promoter region (Figure 7A). We 
hoped that this construct would express PU.l mRNA in a 
manner approximating that of the endogenous PU.l gene 
when transfected into PU.l-‘- ES cells. Since the PU.l-‘- 
ES cells are G416VHygR, a cDNA-encoding resistance to 
the drug puromycin (Pur”) was incorporated to select for 
transformants. The DNA of 25 PurR colonies isolated after 
electroporation of PU.V ES cells was blotted to identify 
transformants harboring intact PU.l transgenes. DNA iso- 
lated from several ES cell transformants showed that 
transgene copy number varied among the ES clones ana- 
lyzed (Figure 78). Clones containing intact transgenes (an 
6.5 kb EcoRl fragment) were differentiated in vitro to deter- 
mine whether PU.l mRNA was being produced. As shown 
in Figure 7C, a number of the transformed clones were 
positive for transgene expression as detected by the RT- 
PCR product for PU.l mRNA. Interestingly, PU.l RNA 
expression appeared to correlate with copy number of the 
transgene (see “rescued” clones R2, Rl 1, and R25; Fig- 
ures 78 and 7C). 
After 11 days in culture, PU.l+‘+ and PU.l-‘- EBs were 
scored for the presence of macrophages along with multi- 
ple PU.l transformed clones. In contrast with PU.l-‘- EBs, 
both PU.l+‘+ EBs and EBs derived from clones R2, Rll , 
R14, R21, and R25 exhibited macrophage production 
upon May-Grunwald-Giemsa staining (Figure 6). To con- 
firm further that macrophages were produced by rescued 
clones, immunocytochemistry was performed on PU.l+‘+, 
PU.l+, and R14 cultures to detect CD1 1 b and F4/60 (Fig- 
ure6). The PU.l rescued clone, R14, showed comparable 
levels of PU.1 expression to R2 and R25 (data not shown). 
It is important to note when the rescued cells were allowed 
to adhere to slides for CD1 1 b and F4/60 staining, they 
did not spread out like the PU.l+‘+ cells and were not as 
abundant. However, CD1 1 b+ and F4/60+ cells were clearly 
present in multiple rescued cultures. PU.l -I- EB cultures 
failed to produce either F4/60+ or CD11 b+ cells. Stable 
transformants lacking an intact PU.1 cDNA transgene also 
failed to produce F4/60+ or CD1 1 b’ cells (data not shown). 
The results of the rescue experiments suggest that no 
inadvertent mutations affecting myeloid cell development 
were introduced at the time of the initial PU.l gene tar- 
geting. More importantly, we conclude that a construct 
containing the PU.l cDNA under the control of its own 
promoter region was sufficient to restore myeloid differen- 
tiation to the PU.l-‘- ES cells in vitro. 
Discussion 
The transcription factor PU.l has been implicated as an 
important regulator of hematopoietic diff erentiation as well 
as proliferation. Our previous studies using gene targeting 
of PU.l demonstrated that there was a multilineage defect 
in the generation of lymphocytic, monocytic, and granulo- 
cytic cells during fetal liver hematopoiesis (Scott et al., 
1994). In the current study, we have focused on how the 
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Figure 7. Rescue of Myeloid Defect in PU.l+ 
ES Cells 
(A) Design of the PU.l complementation vec- 
tor. A6.0 kb PU.l 5’flanking region was placed 
upstream of the 1.2 kb PU.l cDNA. Exons 4 
and 5 of the human growth hormone (hGH) 
gene provide a splicing signal and polyadenyla- 
tion site. 
(6) Southern blot analysis of cell lines 
transfected with the PU.1 complementation 
vector. Homozygous (+) and heterozygous (4 
clones are shown in addition to six rescued(R) 
clones harboring the 6.5 kb transgene. As ex- 
pected, mutant cells exhibit the 5 kb EcoRl re- 
striction fragment, while heterozygous cells 
contain both the 6 kb and 5 kb fragments. Frag- 
ments corresponding to exogenous PU.l DNA 
are 6.5 kb with the exception of clone R31, 
which contains a slightly larger fragment due 
to the loss of one of the EcoRl sites. Clone R7 
does not contain a PU.1 cDNA transgene. 
(C) RT-PCR of rescued clones showing the ex- 
pression of PU.l transcripts. Clone R7 does 
not express PU.l mRNA. 
PU.l mutation affects myeloid development at earlier 
stages of himatopoiesis. Yolk sac hematopoiesis was an- 
alyzed since it has been suggested that yolk sac progeni- 
tors have different characteristics than fetal liver progeni- 
tors (Huang and Auerbach, 1993). When yolk sac cells 
were plated in methylcellulose cultures for progenitor anal- 
ysis, cells derived from PU.l-‘- yolk sacs did not produce 
any GM, G, M, or GEMM colonies. This indicated that the 
earliest myeloid progenitors do not mature in the absence 
of PU.l. The requirement of PU.l at both the yolk sac and 
fetal liver stages of hematopoiesis contrasts with observa- 
tions madewithothertargeted mutations, including c-myb, 
GATA3, and EKLF. For example, homozygous EKLF-‘- 
mice exhibit normal yolk sac hematopoiesis, but develop 
a fatal anemia during fetal liver stage erythropoiesis (Nuez 
et al., 1995; Perkins et al., 1995). Analysis of chimeric mice 
made with PU.l-‘- ES cells indicates that bone marrow- 
derived myelopoiesis in adult animals also requires PU.l 
(E. W. S., R. Fisher, M. C. O., M. C. S., and H. S., unpub- 
lished data). Therefore, PU.l is required for myeloid devel- 
opment at all stages of hematopoiesis (yolk sac, fetal liver, 
and bone marrow). 
During the in vitro differentiation of PU.l-‘- ES cells, 
macrophages and neutrophils were not produced and a 
number of late myeloid genes were not expressed includ- 
ing CD1 1 b, CD84, and M-CSFR. However, early genes 
including CD34, GATA-2, GM-CSFR, G-CSFR, and MPO 
were expressed in PU.l+ EBs at wild-type levels. Further- 
more, GATA-2, GM-CSFR, G-CSFR, and MPO expres- 
sion was equivalent in PU.l+‘+, PU.l+‘-, and PU.l-‘- yolk 
sacs. GM-CSFR and MPO are exclusively found in my- 
eloid cells(Park et al., 1988; Wognum et al., 1994; Lubber? 
et al., 1991). MPO mRNA can be detected in late myelo- 
blastic, promyelocytic, and promonocytic stages of differ- 
entiation, but it decreases upon further myeloid maturation 
(Rosmarin et al., 1989). In our previous study, the MPO 
protein could not be detected in the PU.l-‘- fetal liver cells 
by histochemical staining. However, we do detect low lev- 
els of MPO mRNA in the fetal livers of mutant embryos. 
It is possible that early myeloid precursors transcribe low 
levels of MPO RNA and further differentiation is required 
for efficient expression of MPO protein. The results of the 
RT-PCR analysis of early hematopoietic markers and 
MPO suggest that myelopoiesis is initiated in the absence 
of PU.1. 
It is significant that several putative PU.l target genes 
were not affected by the PU.l mutation: GM-CSFR, 
G-CSFR, and MPO. GM-CSFR and G-CSFR could be 
regulated by the related ETS-family member, Spi-B, which 
is also present in early progenitor cells (G. H. S. and M. 
C. S., unpublished data). Given the importance of GM- 
CSF and G-CSF in myeloid cell growth and maturation, 
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Figure 8. identification of Myeloid Cells by lmmunocytochemical Staining 
May-Grunwald-Giemsa staining (a, d, g) and staining by antibodies for CD1 1 b (b, e, h) and F4/80 (c, f, i) are shown for wild-type (“) cells (a, b, 
c), mutant (-‘-) cells (g, h, i) , and rescued clone R14 cells (d, e, 9. To facilitate an examination of cellular morphologies, phase contrast photomicro- 
graphs are presented. 
the fact that the GM-CSFR and G-CSFR genes are ex- 
pressed without PU.l raises the question of why myelo- 
poiesis is deficient in PU.l mutants. One early myeloid 
target gene for PU.1, c-fes, was expressed at substantially 
lower levels in day 11 PU.l+ EBs. c-fes expression peaks 
at day 11 in PU.l+‘+ EBs due to the expansion of myeloid 
cells. We have recently demonstrated that PU.1 is an im- 
portant regulator of the c-fes promoter in myeloid cells (A. 
Heydemann, G. Juang, K. Hennessy, M. Parmacek, and 
M. C. S., submitted). c-fes is expressed in the same 
cells that are positive for CD34, GATA-2, GM-CSFR, and 
G-CSFR. Given that these cells appear to be present in 
PU.l-‘- EBs, we suggest that PU.l is important for c-fes 
expression in early myeloid cells. c-fes has also been impli- 
cated in myeloid maturation (Vu et al., 1988) and therefore 
its absence could contribute to the arrest in myeloid devel- 
opment that we observe in PU.l mutants. 
Our datashows that hematopoietic progenitors express- 
ing CD34, MPO, GM-CSFR, and G-CSFR are produced 
in the absence of PU.l. This suggests that the earliest 
events in myelopoiesis may be relatively unaffected by a 
mutation in the PU.l gene. However, later myeloid devel- 
opmental events are blocked. We have established an in 
vitro model of early myelopoiesis that is dependent on an 
intact PU.l gene. When PU.l -I- ES cells are differentiated 
in vitro, myeloid cells are not produced. However, the de- 
velopmental deficits of PU.l-‘- ES can be corrected by 
introducing the PU.l cDNA driven by the 8.0 kb PU.l 5 
flanking region. ES cells differentiated in vitro provide an 
excellent model of myeloid development, since differentia- 
tionproceedsfromaprimitiveembryoniccell toadefinitive 
macrophage. The PU.l-targeted ES cells will be useful 
for further studies on the role of PU.1 in the commitment 
of multipotent progenitors to the myeloid lineage. 
Experimental Procedures 
Colony-Forming Assays 
Male and female heterozygous mutant mice were mated to produce 
PU.?embryosforanalysis. All embryos weregenotyped by Southern 
blot analysis of genomic DNA using the probe shown in Figure 3. Yolk 
sac embryos were dissected on day 8.5 and 10.5 of gestation. The 
presence of a vaginal plug on the morning after matings was taken 
as day 0.5 of gestation. Each yolk sac was added to 1 ml of 0.25% 
collagenase (Sigma C-2872, St. Louis, Missouri) in phosphate- 
buffered saline supplemented with 20% fetal bovine serum and incu- 
bated for 1 hr at 37“C with occasional shaking. Yolk sac cells (approxi- 
mately 1 x 1W) were resuspended in 0.25 ml of aMEM and added 
to 1.25 ml of 0.9% methycellulose mixture in 35 mm bacterial grade 
petri dishes. The alpha methylcellulose mixture was purchased from 
Stem Cell Technology (HCC-3230, Vancouver, British Columbia, Can- 
ada) and supplemented with 1% penicillin/streptomysin (100x), 1% 
L-glutamine(200 mM), 1% 8.mercaptcethanol(lOmM), 2 Ulmlerythro- 
poietin (R and D Systems, Minneapolis, Minnesota), and 1.3% poke- 
weed mitogen stimulated spleen cell conditioned medium (Stem Cell 
Technology, HCC-2100). After 7 days of incubation, colonies were 
scored and their identity was confirmed by May-Grunwald-Giemsa 
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(Diff-Quik, Baxter, McGaw Park, Illinois) staining of cytospin prepara- 
tions. 
Semlquantltatlve RT-PCR Analysis 
Total cellular RNA was prepared from EBs by the method of Chomc- 
zynski and Sacchi (1987). Yolk sac and fetal liver RNA was prepared 
using Trizol (GIBCO BRL) according to the instructions of the manufac- 
turer. Total RNA was reverse transcribed (RT) in a 20 ul volume with 
Moloney murine leukemia virus reverse transcriptase (50 U; Perkins- 
Elmer), RNase inhibitor (20 U; Perkin-Elmer), dNTPs (1 mM final con- 
centration; Perkin-Elmer), Oligo d(t),* (2.5 mM final concentration; Per- 
kin-Elmer), MgCI? (5 mM final cont.), KCI (50 mM final concentration), 
and Tris-HCI (pH 8.3) (10 mM final concentration). Samples were incu- 
bated at 42OC for 15 min, at 99OC for 5 min, and at 5OC for 5 min. 
The entire RT reaction was then added to a 80 pl PCR reaction, which 
contained Taq-polymerase (2.5U; Perkin-Elmer), MgCl, (2 mM final 
concentration), KCI (50 mM final cont.), Tris-HCI (pH 8.3) (10 mM final 
concentration), and 500 ng of each primer. In some cases, the PCR 
buffer conditions were modified to optimize the specificity of the reac- 
tion using the Opti-Prime PCR protocol (Stratagene, La Jolla, Califor- 
nia). PCR cycles (30) were performed with the following temperature 
profile: denaturation at 94OC for 1 min. primer annealing at 85OC for 
1 min, and primer extension at 72OC for 2 minutes. Products were 
run on a 1% agarose gel, and visualized with ethidium bromide. The 
primers and the expected sizes of the PCR products are shown in 
Table 2. 
Targeting the PU.l Gene In ES Cells 
G418k/GanCR PU.l heterozygous clones have been described pre- 
viously (Scott et al., 1994). Plasmid pES-PUT was modified by replac- 
ing the PGK-neo cassette with PGK-hyg, creating pES-PU.l. pES- 
PU.l was linearized and introduced by electroporation into 
heterozygous cells. The transfected cells were selected with hygro- 
mycin B (0.125 mg/ml) and gancyclovir (1 mhl) to obtain PU.l homozy- 
gous mutant (‘0 clones. Clones were screened by Southern blot analy- 
sis with the probe shown in Figure3. Wild-type CCE and PU.1 
targeted ES cells were cultured under standard conditions (Keller et 
al., 1993). 
In Vitro Dlfferentlatlon of ES Cells 
CCE and PU.l targeted ES cells were adapted from mitomycin 
C-treated ST0 feeder cells to tissue culture plates coated with 0.1% 
porcine skin gelatin (Sigma, St. Louis, Missouri). After passaging 3-4 
times onto gelatinized plates, these cells were used for in vitro differen- 
tiation. ES cells (4 x 103) were plated into 35 mm bacterial petri dishes 
containing 1.5 ml of 0.9% methylcellulose media supplemented with 
10% fetal bovine serum (Hyclone), kit ligand (25 nglml), IL-la (7.5 x 
102 U/ml), IL-3 (7 U/ml), saturating amounts of GM-CSF, erythropoietin 
(2 U/ml, R and D Systems, Minneapolis, Minnesota), and 4.5 x lo- 
M a-monothioglycerol(Sigma, St. Louis, Missouri). Kit ligand, 11-3, and 
GM-CSF were the gift of Genetics Institute (Boston, Massachusetts). 
IL-la was the gift of Hoffman-LaRoche (Nutley, New Jersey). The ES 
cells were allowed to differentiate into EBs for up to 13 days in a 
humidified 5% CO? atmosphere at 37OC. When differentiated by this 
method, wild-type EBs should produce primitive erythrocytes, defini- 
tive erythrocytes, macrophages, neutrophils, and early megakaryo- 
cytes. At day 11, EBs were picked and cells were identified by cytospin 
preparations stained with May-Grunwald-Giemsa. 
Immunocytochemlstry 
After 11 days of differentiation in 0.9% methylcellulose medium da 
scribed above, 10 EBs were removed and washed with 2 ml of IMDM 
(GIBCO). The EBs were then incubated in trypsin-EDTA for 3 min and 
dissociated by passing through a 2lgauge needle. The cells were 
washed and resuspended in 0.8 ml of IMDM supplemented with 10% 
FCS. Each cell suspension was split into two chambers of an eight- 
chamber slide (Nunc, Napetville, IL) and allowed to incubate overnight 
at 37OC. After removing the media from the chambers, the adherent 
cells were fixed with glutaraldehyde-acetone (Sigma Diagnostics, St. 
Louis, Missouri) and then stained using the Vectastaln ABC-alkaline 
phosphatase kit (Vector Laboratories, Burfingame. California). The pri- 
mary antibody used in the staining procedure was a rat antibody that 
recognizes the mouse macrophage F4/80 antigen (Caltag, San Fran- 
cisco, California). Cells were then incubated with a biotinylated anti-rat 
IgG, which binds to a avidin-biotinyfated alkaline phosphatase com- 
plex. Cells were stained using the Vector Red alkaline phosphatase 
substrate (Vector Laboratories), which produced a bright red pre- 
cipitate. 
Constructlon of PU.l Transgene and SelectIon 
of PU.l Tmnsformants 
A 8.0 kb EcoRI-Sac1 restriction fragment containing PU.l exon 1 and 
5’flanking sequences was subcloned into pBluescript 11 SK(+) along 
with the PU.1 cDNA. Dideoxynucleotide sequencing was performed 
to confirm that the Sac1 site was located 8 bp upstream of the ATG 
translation start codon. The 3’ untranslated exons of human growth 
hormone (including the poly[Aj site) were cloned downstream of the 
PU.l cDNA as a Smal fragment. The PGK-Pup cDNA was placed 
upstream of the 8.0 kb PU.l I’flanking region bysubcloning as aXhol 
restriction fragment. PU.1.‘-EScellswereelectroporatedandselected 
in puromycin (2 ug/ml). 
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Table 2. Oligonucleotide Primers Used for RT-PCR 
Gene Size 5’~Sequence 3’Sequence Reference 
PU.1 500 5%AGTTTGAGAACTTCCCTGAG-3’ 5’-TGGTAGGTCATCI-TCl-fGCGG-3’ Moreau-Gachelin et al., 1989 
p-Actin 934 5’-GTGACGAGGCCCAGAGCAGAG-3’ 5’-AGCGGCCGGACTCATCGTACTC-3’ Alonso et al., 1988 
HPRT 249 5’CACAGGACTAGAACACCTGC-3’ 5”GCTGGTGAAAAGGACCTCT3’ Konecki et al., 1982 
CDllb 822 5”GACCCAGGTTACCGTCTACTAC3’ 5”lTCAGCACTGGGGTCCIlTCAAGC-3’ Pytela, 1988 
CD18 428 5’-AGGACAGTCTAGAGTGTGTGAAGG-3’ 5’-ATTGTGCAGGTCGGAAGACAAGTC-3’ Wilson et al., 1989 
CD34 814 5’GGGTATCTGCCTGGAACTAAGS 5’-ITGCCCACCCAACCAAATCAC-3’ Brown et al., 1991 
CD84 510 5’-TGCAAAGGAAGTCTAGGAAGG-3’ 5%CAGAAGAGTClTGAGlTGGG9’ Lewis et al., 1988 
MPO 895 5’-ATGCAGTGGGGACAGI-TTCTG-3’ 5’-GTCGTTGTAGGATCGGTACTG-3’ Venturelli et al., 1989 
M-CSFR 341 5’-GCGATGTGTGAGCAATGGCAGT3’ 5’-AGACCGTTf-TGCGTAAGACCTG-3’ Schmitt et al., 1991 
G-CSFR 573 S’CTCAAACCTATCCTGCCTCATO-3’ 5’-TCCAGGCAGAGATGAGCGAATG-3’ Fukanaga et al., 1990 
GM-CSFR 598 ScGAGGTCACAAGGTCAAGGTG-3’ 5’-GAI-TGACAGTGGCAGGCI-TC-3’ Park et al., 1992 
c-fes 720 5”TTCGGAGAGGTGITTAGTGGC-3 5’-GCAGATGATGCTGAAACTAGG-3’ Wilks and Kurban, 1988 
p-major 
globin 578 5’-CTGACAGATGCTCTClTGGG9’ 5%ACAACCCCAGAAACAGACA-3’ Konkel et al., 1978 
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